Cargando…
HLA and PF4 antibody production after adenoviral vector SARS-CoV-2 vaccination
Autor principal: | Bouayad, Abdellatif |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Masson SAS.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8445795/ https://www.ncbi.nlm.nih.gov/pubmed/34563798 http://dx.doi.org/10.1016/j.retram.2021.103312 |
Ejemplares similares
-
Preexisting anti-PF4 antibodies are not further triggered upon vaccination with SARS-CoV-2 vector vaccines in a cohort of 400 health care workers
por: Angelika, Wagner, et al.
Publicado: (2022) -
Adenoviral vector vaccine platforms in the SARS-CoV-2 pandemic
por: Mendonça, Samir Andrade, et al.
Publicado: (2021) -
Neutralization of SARS-CoV-2 Variants by mRNA and Adenoviral Vector Vaccine-Elicited Antibodies
por: Tada, Takuya, et al.
Publicado: (2022) -
Neutralizing Antibodies against SARS-CoV-2 and HLA Class I and II Polymorphism
por: Weidner, Lisa, et al.
Publicado: (2021) -
Colchicine May Interfere With the Efficacy of the Adenoviral Vector–Based Vaccine for COVID-19
por: Lin, Cheng-Wei
Publicado: (2022)